Sab Biotherapeutics Stock Fundamentals
| SABS Stock | USD 2.92 0.03 1.02% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
At this time, SAB Biotherapeutics' Research Development is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 3.9 M in 2024, whereas Net Interest Income is likely to drop (204 K) in 2024. SAB | Select Account or Indicator |
SAB Biotherapeutics Company Return On Equity Analysis
SAB Biotherapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SAB Biotherapeutics Return On Equity | -1.75 |
Most of SAB Biotherapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
SAB Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, SAB Biotherapeutics has a Return On Equity of -1.7473. This is 92.71% lower than that of the Biotechnology sector and 95.21% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
SAB Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SAB Biotherapeutics's current stock value. Our valuation model uses many indicators to compare SAB Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SAB Biotherapeutics competition to find correlations between indicators driving SAB Biotherapeutics's intrinsic value. More Info.SAB Biotherapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, SAB Biotherapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value SAB Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.SAB Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in return on equity category among its peers.
SAB Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SAB Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SAB Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | 1.07 M | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 34.24 % | ||||
| Number Of Shares Shorted | 39.93 K | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 18.00 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (12.53 M) | ||||
| EBITDA | (38.08 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Short Ratio | 0.29 X | ||||
| Earnings Per Share | (6.30) X | ||||
| Target Price | 12.4 | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 27.23 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 M | 1.4 M | |
| Total Revenue | 2.2 M | 2.1 M | |
| Cost Of Revenue | 3.7 M | 3.2 M | |
| Stock Based Compensation To Revenue | 1.08 | 1.14 | |
| Sales General And Administrative To Revenue | 10.63 | 11.16 | |
| Research And Ddevelopement To Revenue | 7.38 | 7.74 | |
| Capex To Revenue | 0.09 | 0.08 | |
| Revenue Per Share | 0.41 | 0.39 | |
| Ebit Per Revenue | (17.01) | (16.16) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.